Cirrhotic cardiomyopathy

Summary

Cirrhotic cardiomyopathy (MONDO:0018932) is a disease and 9 clinical trials. Top therapeutic interventions include carvedilol, dobutamine, and empagliflozin. A subtype of non-familial hypertrophic cardiomyopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cirrhotic cardiomyopathy
Mondo ID	MONDO:0018932
Orphanet	57777
ICD-11	1268082489
SNOMED CT	725416005
UMLS	C4511053
MedGen	1391593
GARD	0018852
Is cancer (heuristic)	no

Disease family

This is a subtype of non-familial hypertrophic cardiomyopathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › cardiomyopathy › intrinsic cardiomyopathy › hypertrophic cardiomyopathy › non-familial hypertrophic cardiomyopathy › cirrhotic cardiomyopathy

Related subtypes (2): hypertrophic cardiomyopathy due to intensive athletic training, AL amyloidosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07322237	PHASE4	RECRUITING	DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
NCT01676285	PHASE3	COMPLETED	Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis
NCT06095466	Not specified	RECRUITING	Cirrhotic Cardiomyopathy Based on Point-of-care Echocardiography, Biomarkers and Histology
NCT06431919	Not specified	RECRUITING	Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival
NCT07286643	Not specified	RECRUITING	Echocardiography-guided Cirrhosis and Liver Failure-Intensive Care Protocol Sepsis
NCT07502196	Not specified	NOT_YET_RECRUITING	Heart Problems in Children With Chronic Liver Disease
NCT00250315	Not specified	COMPLETED	DOCICAR: Cardiac Dysfunction in Cirrhosis
NCT04111133	Not specified	UNKNOWN	Ivabradine in Cirrhotic Cardiomyopathy
NCT04969055	Not specified	UNKNOWN	Prevalence, Clinical Features and Risk Factors of Cirrhotic Cardiomyopathy Assessed by Two-dimensional Speckle Tracking Imaging

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARVEDILOL	4	1
DOBUTAMINE	4	1
EMPAGLIFLOZIN	4	1
IVABRADINE	4	1
METOPROLOL SUCCINATE	4	1
CHEMBL5177502	0	1
(R)-Carvedilol	0	1